Novoprotein Scientific Inc. (SHA:688137)
139.41
-11.77 (-7.79%)
Oct 16, 2026, 4:00 PM EDT
Novoprotein Scientific Revenue
Novoprotein Scientific had revenue of 41.25M CNY in the quarter ending June 30, 2026, with 6.73% growth. This brings the company's revenue in the last twelve months to 152.84M, up 9.18% year-over-year. In the year 2025, Novoprotein Scientific had annual revenue of 146.44M with 14.80% growth. That makes Novoprotein Scientific the 33,007th largest company in the world by revenue and 5,072nd in China.
Revenue (ttm)
152.84M
Revenue Growth
+9.18%
P/S Ratio
63.40
Revenue / Employee
219.60K
Employees
696
Market Cap
9.69B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 146.44M | 18.88M | 14.80% |
| Dec 31, 2024 | 127.56M | -25.64M | -16.73% |
| Dec 31, 2023 | 153.19M | -111.36M | -42.09% |
| Dec 31, 2022 | 264.55M | -77.34M | -22.62% |
| Dec 31, 2021 | 341.90M | 162.05M | 90.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 11.19B |
| Pacific Shuanglin Bio-pharmacy | 2.48B |
| Tibet Cheezheng Tibetan Medicine | 2.22B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 2.03B |
| Inner Mongolia Furui Medical Science | 1.64B |
| Shanghai Medicilon | 1.38B |
| Mabwell (Shanghai) Bioscience | 873.99M |
| Chengdu Olymvax Biopharmaceuticals | 759.63M |